Partnering

Most pharmaceutical researchers have experienced the problem of compounds that perform differently in animal testing or clinical trials than had been expected. We apply our BioMAP^® Systems to integrate predictive human biology throughout discovery and development, to fully characterize the performance of compounds in disease-relevant contexts. We work with drug development teams, including program leaders, medicinal chemists and pharmacologists, to identify compounds and compound features that are most relevant to specific clinical biology.

We are collaborating with pharmaceutical partners to improve the efficiency of their drug discovery programs at many stages, including:

• Compound screening for lead discovery
• Lead optimization and structure-activity relationship (SAR) studies
• Characterization of secondary or off-target activities
• Mechanism of action studies
• Development of additional BioMAP® Systems for custom applications
• Re-profiling of stalled clinical-stage compounds
• Evaluation of in-licensing drug candidates

Current partners include:

	Amylin and BioSeek are collaborating on the discovery and development of novel peptide therapeutics for inflammatory conditions. [read more...] [pdf]
	BioSeek is applying its BioMAP® Systems to evaluate UCB Pharma compounds across several compound classes, in support of drug target differentiation, lead optimization, and drug candidate selection activities at UCB. [read more...] [pdf]
	BioSeek is applying BioMAP Systems for the selection of small molecule leads and drug candidates in support of Dainippon Sumitomo’s drug discovery programs in metabolic and inflammatory diseases. [read more...] [pdf]
	BioSeek is working with GlaxoSmithKline (GSK) to identify and differentiate the human biological activities of lead compounds for a variety of inflammatory, metabolic and cardiovascular diseases, in addition to supporting GSK’s phenotypic screening efforts. [read more...] [pdf]
	BioSeek is evaluating the potential human toxicities of a wide spectrum of environmental compounds for the Environmental Protection Agency (EPA) under a three-part grant that, if fully realized, could involve up to 10,000 compounds and $12.8 million in funding. [read more...] [pdf]
	Lexicon and BioSeek are collaborating to help further evaluate selected compounds associated with several of Lexicon's drug discovery programs. [read more...][pdf]